Achieve Life Sciences ACHV Ratios & Valuation
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| Returns | ||||||
| Return on equity | -496.1%-238pp | -257.7%— | —— | —— | —— | |
| Return on assets | -172%-36.1pp | -135.9%-31.2pp | -104.7%-23.2pp | -81.5%+13.3pp | -94.8%+42.5pp | |
| Liquidity | ||||||
| Current ratio | 2.6×-1.8× | 4.4×-0.8× | 5.1×-1.5× | 6.6×+3.1× | 3.5×-2.0× | |
| Quick ratio | 2.6×-1.8× | 4.4×-0.8× | 5.1×-1.5× | 6.6×+3.1× | 3.5×-2.0× | |
| Cash ratio | 2.4×+0.1× | 2.3×-1.0× | 3.3×-2.8× | 6.1×+4.2× | 1.8×-0.1× | |
| Leverage | ||||||
| Debt-to-equity | 0.5×+0.4× | 0.2×+0.1× | 0×0.0× | 0×-0.1× | 0.1×+0.1× | |
| Debt-to-assets | 0.2×+0.1× | 0.1×+0.1× | 0×0.0× | 0×0.0× | 0×0.0× | |
| Per Share | ||||||
| Book value per share | $0.20-59.5% | $0.49-25.1% | $0.66-45.2% | $1.20+305% | $0.30-54.5% | |
| Valuation | ||||||
| Market capitalization | $585.16M+404% | $264.57M+64.4% | $160.98M+21.8% | $132.15M+42.7% | $92.61M-23.5% | |
| Enterprise value | $562.71M+439% | $247.41M+89.8% | $130.33M+59.8% | $81.58M+0.8% | $80.9M-25.4% | |
| Price / book | 54.8×+43.5× | 12.3×+7.5× | 4.8×+1.6× | 3.2×-5.8× | 9×+3.2× | |
| Earnings yield | -8.9%+30.8pp | -20.7%+11.9pp | -32.5%+5.6pp | -38.2%+11.7pp | -49.8%-16.9pp |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Where do Achieve Life Sciences's ratios come from?
- Every ratio is computed from Achieve Life Sciences's SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.